COMMUNIQUÉS West-GlobeNewswire
-
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
29/06/2026 -
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
29/06/2026 -
SPR Wins Fifth Consecutive Northeast Ohio Top Workplaces Award
29/06/2026 -
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
29/06/2026 -
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
29/06/2026 -
Cannabix Technologies Announces First BreathLogix Alcohol Device Deployment to West Africa for Mining Sector
29/06/2026 -
New Video Series “Ahead of Alzheimer’s” Launches Focused on a Renewed Look at Early Alzheimer’s Detection and Preventive Brain Health Care
29/06/2026 -
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
29/06/2026 -
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
29/06/2026 -
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
29/06/2026 -
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29/06/2026 -
Tria Federal Earns Three Positions on NASA SEWP VI Government-Wide IT Contract
29/06/2026 -
Acentra Health Executives Meghan Harris and Verlon Johnson Recognized on Becker’s Healthcare’s 2026 Women in Health IT to Know List
29/06/2026 -
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
29/06/2026 -
SoldierStrong Donates Life-Changing ExoSym® Device to Marine Corps Veteran and Former Police Officer
29/06/2026 -
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
29/06/2026 -
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
29/06/2026 -
Novo Nordisk A/S - share repurchase programme
29/06/2026
Pages